Abstract
This post hoc analysis reports that overall proportion of patients achieving a composite endpoint of HbA1c<7.0% (<53.0 mmol/mol) without hypoglycaemia and weight gain was higher with vildagliptin than glimepiride after 2 years in type 2 diabetes patients inadequately controlled on metformin monotherapy, regardless of age and duration of diabetes.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adamantane / analogs & derivatives*
-
Adamantane / therapeutic use
-
Aged
-
Female
-
Glycated Hemoglobin / metabolism*
-
Humans
-
Hypoglycemia / drug therapy*
-
Hypoglycemic Agents / therapeutic use*
-
Male
-
Metformin / therapeutic use
-
Middle Aged
-
Nitriles / therapeutic use*
-
Pyrrolidines / therapeutic use*
-
Sulfonylurea Compounds / therapeutic use*
-
Vildagliptin
-
Weight Gain / drug effects
Substances
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Nitriles
-
Pyrrolidines
-
Sulfonylurea Compounds
-
glimepiride
-
Metformin
-
Vildagliptin
-
Adamantane